P1B as a free ligand exists in 2 entries. Examples include: 2XKW 4A79

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC19 H20 N2 O3 S
Molecular Weight356.44
Isomeric SMILESCCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1

Chemical Details

Formal Charge0
Atom Count45
Chiral Atom Count1
Chiral AtomsC5
Bond Count47
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01132 Different stereochemistry
  • approved
  • investigational
DescriptionPioglitazone is used for the treatment of diabetes mellitus type 2. Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver.
  • (+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
  • Pioglitazona
  • Pioglitazone
  • Pioglitazonum
SaltsPioglitazone Hydrochloride
Brand Names
  • Accel Pioglitazone
  • Ach-pioglitazone
  • Act Pioglitazone
  • Actoplus Met
  • Actoplus Met XR
Affected OrganismHumans and other mammals
IndicationTreatment of Type II diabetes mellitus
PharmacologyPioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.
Mechanism of actionPioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic β cells.
Route of administration
  • Occlusive dressing technique
  • Oral
  • Alimentary Tract and Metabolism
  • Azoles
  • Blood Glucose Lowering Agents
  • Blood Glucose Lowering Drugs, Excl. Insulins
  • Chemical Actions and Uses
  • A10BD12
  • A10BD09
  • A10BG03
  • A10BD06
  • A10BD05
CAS number111025-46-8

Drug Targets

NameSequence SearchPharmacological ActionActions
Peroxisome proliferator-activated receptor gammaMGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDL...yesagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682